15 Small-Cap Healthcare Stocks Hedge Funds Are Buying

Page 5 of 14

10. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

No. of Hedge Fund Holders: 51

Market Capitalization: $11.53 Billion

Analyst Upside: 60.73%

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotech firm that develops and commercializes treatments for life-threatening rare diseases and medical conditions. The company offers its therapies to speciality pharmacies, pharmaceutical wholesalers, hospitals, distributors, and non-U.S. government agencies. BioMarin has license and partnership agreements with Ares Trading and Catalyst Pharmaceutical.

On May 5, Joon Lee from Truist Financial maintained a Buy rating on BMRN shares with a price target of $92. The analyst kept the rating following solid quarterly results during Q1. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted a total revenue of $745.15 million, up by 15% from a year ago and surpassing estimates by $6.48 million. The company’s adjusted earnings came in at $1.13 per share, up by a whopping 59% and exceeding the consensus of $0.95 per share. The company’s leading therapy VOXZOGO’s global revenue reached $214 million, recording a 40% rise year-over-year. The company is now testing VOXZOGO in its pivotal Phase III trial with children suffering from hypochondroplasia. The company is aiming for a potential launch of VOXZOGO for children with hypochondroplasia in 2027.

Page 5 of 14